{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:36:55Z","timestamp":1788881815514,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"DOI":"10.7759\/cureus.103029","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:54:40Z","timestamp":1770306880000},"source":"Crossref","is-referenced-by-count":1,"title":["Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers for Cardiovascular and Renal Protection in Type 2 Diabetes: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Ayman","family":"Alqurain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen A","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandar A","family":"Alazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maysun A","family":"Aljohani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayan R","family":"Albalawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danah A","family":"Alzughaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulziz F","family":"Alzhrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafie E","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haya N","family":"Alnoumesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahad A","family":"Aloufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alhanouf A","family":"Al Jarad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan S","family":"Alqarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatoun M","family":"Almoqati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A","family":"Mashhour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz A","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f6008","article-title":"Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis","volume":"347","author":"Wu HY","year":"2013","unstructured":"Wu HY, Huang JW, Lin HJ, et al.. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013, 347:f6008. 10.1136\/bmj.f6008","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02318-8","article-title":"Association of diabetes with cardiovascular calcification and all-cause mortality in end-stage renal disease in the early stages of hemodialysis: a retrospective cohort study","volume":"23","author":"Li Q","year":"2024","unstructured":"Li Q, Li P, Xu Z, Lu Z, Yang C, Ning J. Association of diabetes with cardiovascular calcification and all-cause mortality in end-stage renal disease in the early stages of hemodialysis: a retrospective cohort study. Cardiovasc Diabetol. 2024, 23:259. 10.1186\/s12933-024-02318-8","journal-title":"Cardiovasc Diabetol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010256","article-title":"Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: a PRISMA-compliant systematic review and meta-analysis","volume":"97","author":"Lv X","year":"2018","unstructured":"Lv X, Zhang Y, Niu Y, Song Q, Zhao Q. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2018, 97:e0256. 10.1097\/MD.0000000000010256","journal-title":"Medicine (Baltimore)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2017.11.006","article-title":"Angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers for the treatment of hypertension in adults with type 2 diabetes: why we favour angiotensin receptor blockers","volume":"42","author":"Mavrakanas TA","year":"2018","unstructured":"Mavrakanas TA, Lipman ML. Angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers for the treatment of hypertension in adults with type 2 diabetes: why we favour angiotensin receptor blockers. Can J Diabetes. 2018, 42:118-23. 10.1016\/j.jcjd.2017.11.006","journal-title":"Can J Diabetes"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.09.019","article-title":"Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?","volume":"29","author":"Weir MR","year":"2007","unstructured":"Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?. Clin Ther. 2007, 29:1803-24. 10.1016\/j.clinthera.2007.09.019","journal-title":"Clin Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.15562\/bmj.v8i3.1534","article-title":"Comparing the effect of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in heart failure patients with type 2 diabetes mellitus: a systematic review","volume":"8","author":"Febrinasari RP","year":"2019","unstructured":"Febrinasari RP, Martohusodo BI, Kristin E, Nindrea RD, Dwiprahasto I. Comparing the effect of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in heart failure patients with type 2 diabetes mellitus: a systematic review. Bali Med J. 2019, 8:577-81. 10.15562\/bmj.v8i3.1534","journal-title":"Bali Med J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-97-7380-0_5","article-title":"The effect of ACE inhibitors vs. angiotensin receptor blockers on insulin resistance in hypertensive patients","author":"Nandave M","year":"2024","unstructured":"Nandave M. The effect of ACE inhibitors vs. angiotensin receptor blockers on insulin resistance in hypertensive patients. Angiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers. Nandave M (ed): Springer, Singapore; 2024. 223-75. 10.1007\/978-981-97-7380-0_5"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-74720-6_38","article-title":"Diabetes","author":"Pandya N","year":"2024","unstructured":"Pandya N, Patel M. Diabetes. Geriatric Medicine. Wasserman MR, Bakerjian D, Linnebur S, Brangman S, Cesari M, Rosen S (ed): Springer, Cham; 2024. 451-70. 10.1007\/978-3-030-74720-6_38"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/ebmed-2014-110048","article-title":"ACE inhibitors are associated with a reduction in all-cause mortality versus angiotensin II receptor blockers in patients with diabetes mellitus","volume":"19","author":"Harel Z","year":"2014","unstructured":"Harel Z, Silver SA. ACE inhibitors are associated with a reduction in all-cause mortality versus angiotensin II receptor blockers in patients with diabetes mellitus. Evid Based Med. 2014, 19:218. 10.1136\/ebmed-2014-110048","journal-title":"Evid Based Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh ML","year":"2012","unstructured":"McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012, 22:276-82. 10.11613\/BM.2012.031","journal-title":"Biochem Med (Zagreb)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003081","article-title":"Systematic review of the empirical evidence of study publication bias and outcome reporting bias","volume":"3","author":"Dwan K","year":"2008","unstructured":"Dwan K, Altman DG, Arnaiz JA, et al.. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One. 2008, 3:e3081. 10.1371\/journal.pone.0003081","journal-title":"PLoS One"},{"key":"ref14","unstructured":"R Core Team. R. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. (2026). Accessed: January 19, 2026: https:\/\/www.R-project.org\/."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian R","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986, 7:177-88. 10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis","volume":"7","author":"Veroniki AA","year":"2016","unstructured":"Veroniki AA, Jackson D, Viechtbauer W, et al.. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016, 7:55-79. 10.1002\/jrsm.1164","journal-title":"Res Synth Methods"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins JP","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003, 327:557-60. 10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6881","article-title":"A multilevel excess hazard model to estimate net survival on hierarchical data allowing for non-linear and non-proportional effects of covariates","volume":"35","author":"Charvat H","year":"2016","unstructured":"Charvat H, Remontet L, Bossard N, et al.. A multilevel excess hazard model to estimate net survival on hierarchical data allowing for non-linear and non-proportional effects of covariates. Stat Med. 2016, 35:3066-84. 10.1002\/sim.6881","journal-title":"Stat Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson SG","year":"2002","unstructured":"Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted?. Stat Med. 2002, 21:1559-73. 10.1002\/sim.1187","journal-title":"Stat Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger M","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315:629-34. 10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg CB","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994, 50:1088-101. 10.2307\/2533446","journal-title":"Biometrics"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199207233270406","article-title":"Cumulative meta-analysis of therapeutic trials for myocardial infarction","volume":"327","author":"Lau J","year":"1992","unstructured":"Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992, 327:248-54. 10.1056\/NEJM199207233270406","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev J","year":"2008","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008, 61:64-75. 10.1016\/j.jclinepi.2007.03.013","journal-title":"J Clin Epidemiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt GH","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008, 336:924-6. 10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf S","year":"2008","unstructured":"Yusuf S, Teo KK, Pogue J, et al.. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008, 358:1547-59. 10.1056\/NEJMoa0801317","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried LF","year":"2013","unstructured":"Fried LF, Emanuele N, Zhang JH, et al.. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013, 369:1892-903. 10.1056\/NEJMoa1303154","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett AH","year":"2004","unstructured":"Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004, 351:1952-61. 10.1056\/NEJMoa042274","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel A","year":"2007","unstructured":"Patel A, MacMahon S, Chalmers J, et al.. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007, 370:829-40. 10.1016\/S0140-6736(07)61303-8","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf S","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000, 342:145-53. 10.1056\/NEJM200001203420301","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.37970.629537.0D","article-title":"Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)","volume":"328","author":"Marre M","year":"2004","unstructured":"Marre M, Lievre M, Chatellier G, Mann JF, Passa P, M\u00e9nard J. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ. 2004, 328:495. 10.1136\/bmj.37970.629537.0D","journal-title":"BMJ"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti P","year":"2004","unstructured":"Ruggenenti P, Fassi A, Ilieva AP, et al.. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004, 351:1941-51. 10.1056\/NEJMoa042167","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner BM","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al.. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001, 345:861-9. 10.1056\/NEJMoa011161","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis EJ","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al.. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001, 345:851-60. 10.1056\/NEJMoa011303","journal-title":"N Engl J Med"},{"key":"ref34","article-title":"[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]","volume":"163","author":"Parving HH","year":"2001","unstructured":"Parving HH, Lehnert H, Br\u00f8chner-Mortensen J, Gomis R, Andersen S, Arner P. [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]. Ugeskr Laeger. 2001, 163:5519-24.","journal-title":"Ugeskr Laeger"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller H","year":"2011","unstructured":"Haller H, Ito S, Izzo JL Jr, et al.. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011, 364:907-17. 10.1056\/NEJMoa1007994","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study","volume":"54","author":"Imai E","year":"2011","unstructured":"Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda M, Makino H. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011, 54:2978-86. 10.1007\/s00125-011-2325-z","journal-title":"Diabetologia"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000024416.33113.0a","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect","volume":"106","author":"Viberti G","year":"2002","unstructured":"Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002, 106:672-8. 10.1161\/01.cir.0000024416.33113.0a","journal-title":"Circulation"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f B","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Kjeldsen SE, et al.. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002, 359:995-1003. 10.1016\/S0140-6736(02)08089-3","journal-title":"Lancet"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.07.043","article-title":"Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease","volume":"112","author":"Yamashita K","year":"2013","unstructured":"Yamashita K, Kondo T, Muramatsu T, et al.. Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease. Am J Cardiol. 2013, 112:1750-6. 10.1016\/j.amjcard.2013.07.043","journal-title":"Am J Cardiol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803053381002","article-title":"Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans","volume":"338","author":"Bellamy R","year":"1998","unstructured":"Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med. 1998, 338:640-4. 10.1056\/NEJM199803053381002","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.4.597","article-title":"Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM","volume":"21","author":"Tatti P","year":"1998","unstructured":"Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998, 21:597-603. 10.2337\/diacare.21.4.597","journal-title":"Diabetes Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/460717-angiotensin-converting-enzyme-inhibitors-versus-angiotensin-receptor-blockers-for-cardiovascular-and-renal-protection-in-type-2-diabetes-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:54:41Z","timestamp":1770306881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/460717-angiotensin-converting-enzyme-inhibitors-versus-angiotensin-receptor-blockers-for-cardiovascular-and-renal-protection-in-type-2-diabetes-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.103029","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,5]]}}}